Axiogenesis is a leading provider of commercial-grade in vitro differentiated cell types (e.g., cardiac, neuronal) derived from human induced pluripotent stem cells (iPSCs), along with validated assays, which enable drug development. Assays for each cell type have been developed for advanced drug discovery, disease and tissue modeling, safety pharmacology, and in vitro toxicology applications.
Axiogenesis' innovative and proprietary cell types and assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency.
iPSC-Derived Cardiomyocytes and Neural Cells
Axiogenesis’ cardiac products encompass hiPSC-derived Cor.4U® cardiomyocytes and vCor.4UTM ventricular cardiomyocytes used in cardiac safety and HTS applications as well as isogenic FibroCor.4UTM electro-competent cardiac fibroblasts used in tissue modeling. The neural cell portfolio spans Peri.4UTM peripheral neurons (for structural and functional toxicity assays, novel neurotoxin screening), CNS.4UTM central nervous system cell mix (for neurotoxicity assays and CNS disease modeling), Dopa.4UTM dopaminergic neurons (for neurodegenerative disease models, neurotoxicity screening), and Astro.4UTM astrocytes (for neuronal co-culture). Products in development include iPSC-derived sensory neurons and matured cardiomyocytes. As a result of its in-house assay capability, Axiogenesis can provide expert scientific support in order to facilitate selection and quick implementation of validated assays and technologies.